Recent Updates — AEON
AEON Biopharma announced receipt of official minutes from its FDA Type 2b meeting regarding the biosimilar development pathway for ABP-450, a proposed biosimilar to BOTOX. The FDA agreed in principle with AEON's two-stage comparative pharmacodynamic study design using CMAP measurement and indicated that previously completed Daewoong Pharmaceutical studies may be submitted as supportive evidence subject to scientific bridging. Consequently, the condition for accelerating the expiration of Two-Year Milestone Warrants was satisfied, causing them to expire on November 16, 2026. AEON plans to submit an IND for the CMAP study in Q4 2026 and initiate it in Q1 2027. The company operates as a biopharmaceutical firm developing biosimilars.
AEON Biopharma reported a net loss of $1.2 million for the second quarter ended June 30, 2026, driven by $5.9 million in operating expenses. The company completed an underwritten public offering in July 2026, generating approximately $13.6 million in net proceeds and up to $34.0 million in potential gross proceeds from milestone warrants. These funds extend the cash runway into the first quarter of 2027. AEON also restored compliance with NYSE American listing requirements on August 3, 2026. The company is advancing ABP-450 as a biosimilar to BOTOX for therapeutic use and expects FDA feedback in the second half of 2026 regarding clinical pharmacology and comparative study requirements. AEON Biopharma operates in the biopharmaceutical industry, developing biosimilars.
AEON Biopharma announced it regained compliance with NYSE American continued listing standards following an underwritten public offering that closed on July 15, 2026. The company sold 17,851,599 shares and pre-funded warrants for 24,837,008 additional shares, plus 4,696,102 shares from an over-allotment exercise on July 23, 2026. Net proceeds totaled approximately $13.6 million, with potential for up to $34.0 million more upon cash exercise of milestone warrants. This capital raise restored stockholders' equity above the $4.0 million minimum requirement, resolving deficiencies under Sections 1003(a)(i) and 1003(a)(ii). The NYSE American '.BC' indicator is expected to be removed from its trading symbol. AEON Biopharma operates in the biopharmaceutical industry, developing ABP-450 as a biosimilar to BOTOX for therapeutic use.
AEON Biopharma, Inc. issued and sold 4,696,102 shares of Class A common stock to underwriters following the partial exercise of an over-allotment option, generating approximately $1.5 million in gross proceeds and $1.4 million in net proceeds. This transaction follows a previously reported public offering completed on July 15, 2026. AEON Biopharma, Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic solutions.
AEON Biopharma, Inc. completed an underwritten public offering on July 15, 2026, consisting of 17,851,599 shares of Class A common stock and 24,837,008 pre-funded warrants, plus an over-allotment of 6,403,290 shares/warrants exercised by the representative. The offering included two-year and five-year milestone warrants tied to regulatory and clinical developments for ABP-450. The company received approximately $12.2 million in net proceeds, with gross proceeds from the initial offering expected at $13.75 million. Potential additional gross proceeds of up to $29.6 million could be realized through the cash exercise of milestone warrants. Net proceeds are intended for working capital and comparative analytical testing of ABP-450 to support biosimilarity to BOTOX®. AEON Biopharma is a biopharmaceutical company developing biosimilar products.